Benitec Biopharma Inc.
12.45USD
-0.2750 (-2.16%)
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 73.0K | 75.0K | 0.0 | — | 0.0 | 18.2M |
| Q1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Q2 | 25.0K | 14.0K | 0.0 | 0.0 | 0.0 | — |
| Q3 | 48.0K | 54.0K | 0.0 | 0.0 | 0.0 | — |
| Q4 | 0.0* | 7.0K* | 0.0* | — | 0.0 | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | -.486 | -.543 | -.610 | -1.05 | -.985 | -1.12 |
| Q1 | -.135 | -.141 | -.169 | -.180 | -.220 | -.278 |
| Q2 | -.129 | -.128 | -.189 | -.260 | -.260 | — |
| Q3 | -.087 | -.103 | -.115 | -.380 | -.240 | — |
| Q4 | -.135* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
| -.129* |
| -.129* |
| -.210 |
| -.265 |
| — |